The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Mar 2020
Randomized Controlled TrialUpadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
Atopic dermatitis is a chronic inflammatory skin disease characterized by pruritic skin lesions. ⋯ A dose-response relationship was observed for upadacitinib efficacy; the 30-mg once-daily dose showed the greatest clinical benefit. Dose-limiting toxicity was not observed.